MedPath

[18F]-flutemetamol amyloid imaging along the continuum from normal cognitive status to Alzheimer's disease dementia.

Not Applicable
Completed
Conditions
Alzheimer's disease, mild cognitive impairment (MCI), and cognitive intact healthy control (HC) subjects
Registration Number
JPRN-jRCT1091220124
Lead Sponsor
Shizuo Hatashita
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria

AD, MCI and HC subjects undergo cognitive testing, [11C]-PIB PET and [18F]-flutemetamol PET. Informed consent is obtained.

Exclusion Criteria

Other degenerative disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath